Decision to list medical devices supplied by Boston Scientific New Zealand Limited
We are pleased to announce the approval of a listing agreement for the supply of medical devices to DHBs.
What we’re doing
We are pleased to announce the approval of a listing agreement with Boston Scientific New Zealand Limited (“Boston”) for the supply of:
In summary this will result in:
- Boston’s products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 February 2022 under a national agreement that all DHBs may purchase under (“Agreement”); and
- DHBs being able to continue to purchase other suppliers’ brands of electrophysiology equipment and consumables, and ICDs, pacemakers and associated products.
Who we think will be most interested
- DHB clinical staff in a range of clinical settings including:
- Cardiac Service Managers
- Cardiac Surgeons
- Cardiology unit staff
- DHB procurement and supply chain personnel
- Suppliers and wholesalers
Details about this decision
In September 2020, Pharmac issued a Registration of Interest (“ROI”) for ranges of medical devices, including electrophysiology equipment and consumables, considered for listing on the Pharmaceutical Schedule.
These ROI were undertaken to transfer the responsibility for management of products in these categories from NZ Health Partnerships to Pharmac. The ROI was for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
As there were no material changes made to the terms and conditions that are currently in place, Pharmac decided that consultation on the provisional Agreement was not required and Pharmac has decided to list electrophysiology equipment and consumables, and ICDs, pacemakers and associated products in Part III of Section H of the Pharmaceutical Schedule from 1 February 2022.
DHBs can continue to choose which products in both these categories they will purchase, including from other suppliers. DHBs that purchase these products from Boston must do so under the terms and conditions, including pricing, in the Pharmac Agreement from 1 February 2022.
The Agreement includes terms and conditions for training and education to be provided by Boston on the appropriate use of its products, which is to be provided at times and in formats as agreed with individual DHBs.
If you have any questions about this decision, you can email us at firstname.lastname@example.org; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.